 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...4567891011121314...203204» |
- Zeposia (ozanimod) / BMS
REAL-WORLD RETROSPECTIVE ANALYSIS OF OZANIMOD AND ASSOCIATED CORTICOSTEROID SPARING FOR THE TREATMENT OF ULCERATIVE COLITIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7469;
Fewer of these pts cycled through AT and initiated OZA sooner after UC diagnosis than pts who overused CS. This suggests that pts may benefit from initiating OZA earlier instead of prolonging CS cycling.
- Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
DELAYED USTEKINUMAB AND ADALIMUMAB RESPONDERS HAVE SIMILAR OUTCOMES AS EARLY RESPONDERS IN BIOLOGIC-NAIVE CROHN'S DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7411;
Biomarker decline through the initial 8 weeks of therapy can help to identify delayed responders. Rates of delayed response as reported in clinical trial of CD may vary depending on trial design.
- NETWORK META-ANALYSIS COMPARING EFFICACY OF CONVENTIONAL THERAPY AND BIOLOGICS TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN PATIENTS WITH CROHN'S DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7410;
When prophylactic therapy is indicated, biologics appear as the best therapeutic option to prevent of endoscopic POR. Due to lower effectiveness, the use of 5-ASA and thiopurines should be limited in this situation.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
SUPERIOR TREATMENT PERSISTENCE WITH INFLIXIMAB VERSUS ADALIMUMAB IN FISTULISING CROHN'S DISEASE: REAL-WORLD REGISTRY DATA FROM THE PERSISTENCE AUSTRALIAN NATIONAL IBD COHORT (PANIC) STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7409;
The median age was 35 years (interquartile range (IQR): 25-47), with 3,006/6,394 (47.0%) females. Via therapy, 2,983/6,394 (46.7%) were on adalimumab and 3,411/6,394 (53.3%) on infliximab; 40.6% (2,595/6,394) used thiopurine, and 10.6% (680/6,394) used methotrexate co-therapy.
- BAYESIAN NETWORK META-ANALYSIS OF THE EFFICACY OF ADVANCED THERAPIES FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS NA (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7396;
Via therapy, 2,983/6,394 (46.7%) were on adalimumab and 3,411/6,394 (53.3%) on infliximab; 40.6% (2,595/6,394) used thiopurine, and 10.6% (680/6,394) used methotrexate co-therapy. In the NMA for clinical remission in the induction phase, etrasimod 2 mg had a statistically significant benefit over adalimumab 80/40 mg and 160/80 mg (RR [95% CrI] for treatment vs etrasimod 0.49 [0.29
- PERSISTENCE OF ADVANCED THERAPIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE COHORT STUDY USING LARGE HEALTHCARE CLAIMS DATABASE IN JAPAN (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7393;
As an index treatment, ustekinumab maintained high persistence through 2 years from the index date both in CD and UC. This data provides valuable information on the management of patients living in Japan with IBD under real-world setting.
- Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
BIOLOGIC USE PROTECTS AGAINST ADVERSE OUTCOMES IN PATIENTS WITH INFLAMMATORY DISEASE AFTER SARS-COV-2 INFECTION: A MULTI-SITE RETROSPECTIVE COHORT STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6989;
Biologics may protect IBD patients with COVID-19 from 90-day adverse outcomes, especially the unvaccinated group. Regardless of their vaccination status, prednisone use increased the risk of hospitalization post-COVID-19.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
ATTAINING EARLY ANTI-TNF EXPOSURE TARGETS IS ASSOCIATED WITH IMPROVED RATES OF ENDOSCOPIC HEALING AND TRANSMURAL HEALING IN CHILDREN WITH CROHN'S DISEASE (151A - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6470;
Achieving anti-TNF exposure targets during induction and early maintenance positively influences CD outcomes. Incorporation of these PK parameter thresholds into precision dosing platforms will allow clinicians to personalize anti-TNF dosing regimens.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
EXTENSIVE PROTEOMIC ANALYSIS IDENTIFIES A CROHN'S DISEASE CORE PROTEOME AND ANTI-TNF TREATMENT RESPONSE PROFILE FOR CHILDREN WITH CROHN'S DISEASE (101 - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5999;
Incorporation of these PK parameter thresholds into precision dosing platforms will allow clinicians to personalize anti-TNF dosing regimens. CD patients were enrolled (10/2019-12/2022) at four pediatric centers with longitudinal blood and stool specimens collected prior to the start of either infliximab (IFX) or adalimumab (ADAL) and throughout this observational study...Starting with 7312 protein analytes, we identified 2556 differently abundant proteins (1647, up, 909 down, Fig1a-b) between the 43 steroid-na
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
LOW TROUGH DRUG LEVELS LEAD TO HIGHER RATES OF TREATMENT FAILURE AFTER 6 MONTHS OF CONTINUOUS THERAPY WITH AN ANTI-TNF MEDICAITON IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: POST-HOC ANALYSIS OF THE COMBINE TRIAL (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5519;
Consistent with prior literature, higher drug levels were associated with reduced risk of treatment failure in the maintenance phase of therapy. This data may and help guide therapeutic drug monitoring for patients initiating anti-TNF therapy and further inform shared decision-making regarding combination therapy or monotherapy.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
HIGH BODY MASS INDEX AND RESPONSE TO ANTI-TNF THERAPY IN PEDIATRIC CROHN DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5510;
Higher BMI was associated with lower drug trough levels. Standard FDA approved adalimumab dosing may be insufficient for overweight children with CD.
- RATES OF ESCALATION TO ADVANCED THERAPY IN PATIENTS WITH ULCERATIVE PROCTITIS AT SIX MONTHS, ONE YEAR, AND TWO YEARS POST DIAGNOSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5339;
We excluded those on prior advanced therapy (azathioprine, methotrexate, mercaptopurine, infliximab, golimumab, adalimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod)...Anti-TNFs were the most used medication class, with infliximab or adalimumab being the most frequently used agents. Our data suggests a mostly benign disease course in patients with UP with a low percentage requiring advanced therapies.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
OUTCOMES OF LONG-TERM ANTI-TNF THERAPY BEYOND 10 YEARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5327;
The mean total duration of anti-TNF therapy was 13.5 years (range 10-24 years). There were 307 infliximab and 72 adalimumab users.
- ANTI TNF MEDICATIONS BUT NOT JAK INHIBITORS ARE ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM. DATA FROM A LARGE NATIONAL COHORT. IS IT THE MECHANISM OF THE DRUG OR THE DISEASE? (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5303;
There were 307 infliximab and 72 adalimumab users. We compared patients on various IBD therapies [non-advanced (prednisone, budesonide, 5-aminosalicylates), immunomodulators (IM), anti-TNF (infliximab, adalimumab, certolizumab, golimumab), anti-integrin (vedolizumab), anti-IL12/23 (ustekinumab, rizankinumab), JAK inhibitors (tofacitinib, upadacitinib)], and statins for outcomes of VTE
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
FEASIBILITY STUDY OF A POINT-OF-CARE ASSAY FOR RAPID DETERMINATION OF ANTI-TNF? BIOLOGICS IN CAPILLARY BLOOD (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5253;
This study furthermore demonstrated the assays are well suited to be used in a POC setting, such as infusion centres, rather than in a laboratory. Both assays are standardized to WHO reference material.
- COMPARATIVE EFFICACY OF BIOLOGICS AND SMALL MOLECULE THERAPIES IN IMPROVING HEALTH RELATED QUALITY OF LIFE IN ULCERATIVE COLITIS; SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4911;
All medications were superior to placebo except etrolizumab (OR= 0.87 [95% CI 0.39; 1.92]) Per SUCRA score, tofacitinib ranked highest (88%), followed by golimumab (77%)...In addition, guselkumab ranked highest followed by tofacitinib and upadacitinib in improving HRQoL. During maintenance of remission, Tofacitinib ranked highest.
- EFFICACY AND SAFETY OF ADVANCED MEDICAL TREATMENTS FOR MAINTENANCE OF REMISSION IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4910;
Tofacitinib was not effective and there was no data available for immunomodulators and combination therapies for this outcome...Conclusion On network meta-analysis immunomodulators and advanced therapies for maintenance phase, combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for prevention of clinical relapse. There was moderate to high certainty evidence to suggest newer advanced therapies are effective in prevention of loss of clinical response.
- Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
EFFICACY AND SAFETY OF BIOLOGICAL TREATMENTS FOR MAINTENANCE OF SURGICALLY INDUCED REMISSION IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4907;
Conclusion On network meta-analysis, adalimumab had a large magnitude of effect size for preventing clinical and endoscopic relapse (low certainty), vedolizumab a large magnitude for preventing endoscopic relapse (low certainty) and 5-ASA a small magnitude result for preventing clinical relapse (low certainty). Overall certainty of evidence is very low to low suggesting need for further research in this
- ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED CANCER RATES IN IBD PATIENTS (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4645;
Importantly, there was not an increase in malignancies in older IBD patients treated with OSM. While further studies and longer follow up periods are needed to validate these findings, our results provide reassurance regarding the safety of OSM in IBD.
- BIOLOGICS AND JAK INHIBITORS DECREASE MAJOR CARDIOVASCULAR EVENTS (MACE) IN IBD PATIENTS. DATA FROM A LARGE NATIONAL COHORT. IS IT THE MECHANISM OF THE DRUG OR CONTROL OF DISEASE? (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4643;
IBD patients treated with biologics and JAK inhibitors are less likely to have MACE with the most notable risk reduction seen with anti-TNF medications after adjusting for CV risk factors. Studies are needed to see whether this decrease in risk is due to control of the disease or mechanism of a drug.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
REAL LIFE MANAGEMENT OF PATIENTS WITH ACTIVE PERIANAL FISTULIZING CROHN'S DISEASE (ALERT-CD STUDY) (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3298;
This study demonstrated a high adherence to international guidelines on pCDmanagement concerning imaging at diagnosis, endoscopic evaluation for concomitant proctitis and treatment with anti-TNF agents. Adherence to use of antibiotics for symptoms, performance of fistula surgery aiming at fistula closure and decision making in a MDT is moderate and standardization may optimize pCD management.
- Humira (adalimumab) / AbbVie
THE INTRA-PATIENT VARIABILITY OF ADALIMUMAB CLEARANCE DURING AN INTENSIVE SAMPLING STUDY OF CROHN'S DISEASE PATIENTS RECEIVING MAINTENANCE THERAPY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3287;
Adherence to use of antibiotics for symptoms, performance of fistula surgery aiming at fistula closure and decision making in a MDT is moderate and standardization may optimize pCD management. Of 7 patients without sustained clinical and biochemical remission, two presented with optimal concentrations (> 10
- Humira (adalimumab) / AbbVie
PRECISION DOSING TEST FOR OPTIMIZING ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EVIDENCE STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3286;
This data validates the consistent relationship of individualized PK parameters with disease activity and physician decision making. Low ADA concentration and high CL are associated with higher risk of therapy discontinuation and active disease, therapy optimization with precision-guided dosing is likely to mitigate these risks.
- Humira (adalimumab) / AbbVie
SUSTAINED PRESENCE OF PHARMACOKINETIC PREDICTIVE FACTORS IS ASSOCIATED WITH IMPROVED THERAPEUTIC OUTCOME DURING MAINTENANCE OF CROHN'S DISEASE PATIENTS ON ADALIMUMAB (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3284;
Sustained concentration and lower clearance likely reflect the availability of drug in sufficient quantity, and effective retention of ADA, for neutralization of the inflammatory burden. These measures may be relevant in clinical practice.
- Humira (adalimumab) / AbbVie
THE ASSOCIATION BETWEEN 6-THIOGUANINE NUCLEOTIDE LEVELS, ADALIMUMAB DRUG CONCENTRATIONS, ANTI-ADALIMUMAB ANTIBODIES AND DRUG CLEARANCE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3279;
Background : The use of thiopurines can augment the pharmacokinetics (PK) of infliximab and offer better clinical outcomes...Method : We interrogated a large clinical laboratory database of adult patients with Crohn's disease (CD) or ulcerative colitis (UC) treated with thiopurines (6-MP or azathioprine) and adalimumab (40 mg every other week or weekly) who had both RBC 6-TGN levels and serum ADA concentrations measured within 30 days using reverse phase and size exclusion liquid chromatography coupled with UV and fluorescence detection, respectively...Lower CL is also associated with higher 6-TGN levels. Optimizing thiopurines, could potentially have a role improving ADA PK in clinical settings, even in patients that had undergone dose escalation.
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
POOR PROGNOSTIC FACTORS OF PHARMACOKINETIC ORIGIN PREDICT OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH ANTI-TUMOR NECROSIS FACTOR-? (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3273;
Cumulatively, each incremental increase in PPF of PK origin resulted in lower likelihood of endoscopic remission (OR=0.36 95%CI: 0.19-0.66; p<0.001). Conclusion : We conclude that PPF of PK origin, both higher Clearance and carriage of HLA DQA1*05, impact outcomes in patients with IBD.
- Humira (adalimumab) / AbbVie
HIGHER MAINTENANCE ADALIMUMAB CONCENTRATION IS ASSOCIATED WITH COMPLETE FISTULA HEALING IN PATIENTS WITH PERIANAL FISTULIZING CROHN'S DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3261;
In the largest TDM cohort of patients with perianal fistulizing CD treated with ADM, we found that higher maintenance ADM concentrations are associated with CFH. Moreover, an ADM maintenance concentration threshold of 12.1 ?g/ml may be a target for TDM to achieve CFH in patients with perianal fistulizing CD.
- Humira (adalimumab) / AbbVie
CROHN'S DISEASE STRICTURES RESPOND TO ADALIMUMAB DRUG TREATMENT. LONG TERM (4.5 YEARS) RESULTS OF THE STRIDENT RANDOMISED CONTROLLED TRIAL. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3234;
64 of 77 (83%) patients completed at least 12 months of adalimumab therapy as part of the study while 13 (17%) withdrew: 8 surgery, 5 other. The 77 were assessed for outcomes at a minimum of 4 years after study entry (median 57 (IQR 51.7-59.5) months).
- PATIENTS IN TRIALS OF MODERATE-TO-SEVERE UC WHO ARE EXPOSED TO PLACEBO ARE MORE LIKELY TO SUFFER HARM THAN THOSE RECEIVING ACTIVE TREATMENT: THE LACK OF CLINICAL EQUIPOISE IN TRADITIONAL STUDY DESIGNS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3207;
Induction treatment responders re-randomized for maintenance to PBO experienced greater harms (lower NNH) than treat-through PBO patients. These findings raise concern about clinical equipoise in PBO-controlled trials of moderate-to-severe UC and support ongoing efforts to design trials with active comparator arms and adaptive or platform methodologies.
- PATIENTS IN TRIALS OF MODERATE-TO-SEVERE CD WHO ARE EXPOSED TO PLACEBO ARE MORE LIKELY TO SUFFER HARM THAN THOSE RECEIVING ACTIVE TREATMENT: THE LACK OF CLINICAL EQUIPOISE IN TRADITIONAL STUDY DESIGNS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3206;
There was an increased probability of SAEs for patients exposed to PBO in 4/11 induction (NNH PBO = 6.6-24.7; NNH Rx = 4.8-26.6), 5/6 TT, and 8/9 RR (NNH TTPBO = 3.4-15.1; NNH TTRx =3.6-19.0; NNH RRPBO = 6.0-13.1; NNH RRRx = 8.1-11.9). Patients were at increased probability of DEAEs in the PBO arm of 5/8 induction (NNH PBO = 6.3-12.3; NNH Rx = 10.0-62.0), 5/5 TT, and 6/9 RR (NNH TTPBO = 3.1-8.5; NNH TTRx = 4.4-24.0; NNH RRPBO = 2.5-7.0; NNH RRRx = 7.1-9.4).
- etrolizumab (RG7413) / Roche
MOLECULAR CHARACTERIZATION OF RESPONSE TO ETROLIZUMAB AND ANTI-TNF REVEALS TREATMENT REFRACTORY ULCERATIVE COLITIS IS ASSOCIATED WITH ABUNDANCE OF RESIDUAL NEUTROPHIL SUBSETS AND ACTIVE FIBROBLAST POPULATIONS (101 - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2634;
Conclusions : Our data provide longitudinal gene signatures associated with etrolizumab and adalimumab response in patients with UC and reveal single-cell resolution of the cell types and their interactions that may underlie these findings. We also reveal novel insights into neutrophil states and their signaling pathways that may represent resistance mechanisms in UC patients resistant to biologic therapies.
- Humira (adalimumab) / AbbVie
COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN'S DISEASE. (146AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2193;
Effectiveness was similar, with an incremental effectiveness of 0.008 in favor of the FCP strategy. Thus, the FCP strategy strongly dominated the ileocolonoscopy strategy over 18 months.
- tofacitinib / Generic mfg.
COMBINATION THERAPY OF THE FXR AGONIST FXR314 WITH TOFACITINIB IN MODELS OF INFLAMMATORY BOWEL DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1298;
When administered at sub-efficacious doses, FXR314 and tofacitinib synergistically improved colitis, similar to the effects seen with each agent alone at optimal dose levels. In conclusion, this study, demonstrates the synergistic potential of combining the non-bile acid FXR agonist FXR314 with the JAK inhibitor tofacitinib, supporting the notion of FXR314 as both a monotherapy and a combination therapy in IBD.
- IT'S TIME TO INCLUDE CAPSULE ENDOSCOPY TO ASSESS MUCOSAL ACTIVITY AS PART OF THE 'TREAT-TO-TARGET' STRATEGY IN CROHN'S DISEASE: A REAL-LIFE EXPERIENCE FROM A REFERENCE CENTER IN ARGENTINA. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1213;
These results suggest that CE could be incorporated into the'treat-to-target'strategy for patients with CD. However, randomized controlled trials are required to confirm this recommendation.
- CHARACTERIZING PRACTICE PATTERNS IN DISEASE ACTIVITY MONITORING OF INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING BIOLOGIC INITIATION WITHIN A LARGE REGIONAL HEALTHCARE SYSTEM (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1186;
Symptomatic patients completed endoscopy at nearly triple the rate of asymptomatic patients, suggesting deferral of short-term diagnostic endoscopy for asymptomatic patients. Subsequent research should include further subgroup analyses, assess variation in IBD outcomes between patients completing TTT versus routine care, and consider explanations for limited uptake of TTT for endoscopy and biomarkers.
- INVESTIGATING VENOUS THROMBOEMBOLIC EVENTS ACROSS IBD THERAPIES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1160;
The rate of GI bleeding is also decreased in patients on advanced IBD therapy, with or without concomitant treatment with anticoagulants. Our data support communicating the decreased rates of DVT, pulmonary embolism, and GI bleeding with patients when discussing the benefits of advanced therapies.
- PARADOXICAL RISK OF RHEUMATOID ARTHRITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS EXPOSED TO TUMOR NECROSIS FACTOR INHIBITORS: A PROPENSITY MATCHED MULTI-NETWORK STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1155;
Conclusion In this large retrospective case-control study among IBD patients, we did not detect an association between anti-TNF therapy and paradoxical increased risk of RA when compared to IBD patients who received non-anti-TNF advanced and non-advanced IBD therapy. Our results are consistent with TNF-?'s role as a major proinflammatory cytokine and subsequent modulation of systemic inflammation by anti-TNF medications.
- BIOLOGICS AND ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED MAJOR ADVERSE CARDIOVASCULAR EVENTS OR VENOUS THROMBOEMBOLISM IN OLDER IBD PATIENTS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1144;
Older IBD patients treated with biologics or OSM were not at increased risk of MACE or VTE. While further studies and longer follow up periods are needed to confirm these findings, our results provide reassurance regarding the safety of these medications in IBD.
- Humira (adalimumab) / AbbVie
A HUMAN PRIMARY CELL MODEL OF THE INFLAMED COLON WITH UTILITY FOR IBD THERAPEUTIC DRUG DISCOVERY AND DEVELOPMENT. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_876;
antibody) and tofacitinib (STAT inhibitor). Together, these data highlight the ability to use RepliGut
- Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
PROACTIVE PATIENT ENGAGEMENT TO PROMOTE REPRESENTATIVE PATIENT POPULATIONS FOR FUTURE TRIALS OF DUAL TARGETED THERAPIES IN INFLAMMATORY BOWEL DISEASES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_714;
P4
ExiGem (NCT06095128) is a phase 4, open-label, single-arm study to evaluate the induction of response and remission following treatment with vedolizumab and tofacitinib in patients with moderate to severe UC...Conclusion Here we describe the study designs for the novel EXPLORER 2.0 and ExiGem trials of combined targeted IBD therapies. By proactively engaging patients to gain insights on barriers to enrollment we identified opportunities to improve the study designs to optimize patient recruitment.
- | Journal: Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period. (Pubmed Central) - Mar 13, 2024
By proactively engaging patients to gain insights on barriers to enrollment we identified opportunities to improve the study designs to optimize patient recruitment. DBT seems to be an effective alternative therapeutic option for patients with moderate and severe IBD.
- | Humira (adalimumab) / AbbVie
Trial initiation date, Trial primary completion date, Checkpoint inhibition: Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (clinicaltrials.gov) - Mar 13, 2024
P2, N=30, Not yet recruiting, Sponsor: Tom Appleton
DBT seems to be an effective alternative therapeutic option for patients with moderate and severe IBD. Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Aug 2025 --> Nov 2025
- | Journal: Safety and efficacy of biologic immunosuppressive treatment in juvenile idiopathic arthritis associated with inborn errors of immunity. (Pubmed Central) - Mar 12, 2024
Results suggest that the use of immunosuppressive biological therapies can control disease activity in these patients. No adverse drug-related reactions were observed during the follow-up.
- | Humira (adalimumab) / AbbVie
Enrollment open: GUIDE: Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease (clinicaltrials.gov) - Mar 12, 2024
P1/2, N=21, Recruiting, Sponsor: University Medical Center Groningen
No adverse drug-related reactions were observed during the follow-up. Not yet recruiting --> Recruiting
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Retrospective data, Journal: Is tumor necrosis factor-? monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis. (Pubmed Central) - Mar 11, 2024
Proactive TDM is more suitable for IBD patients treated with ADA and has obvious advantages over reactive TDM. We recommend proactive TDM in IBD patients who are treated with ADA.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Detection of infliximab, adalimumab, and anti-drug antibodies: Development and validation of new monotest, automated assays on multiparametric instrument. (Pubmed Central) - Mar 11, 2024
During preclinical development, these kits resulted as sensitive, specific, accurate, and able to quantify either the reference drug or the corresponding biosimilars. All these features support their use in clinical practice for therapeutic drug monitoring of patients with inflammatory diseases under treatment with IFX or ADL.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Humira (adalimumab) / AbbVie
Journal, Immune cell: Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNF?. (Pubmed Central) - Mar 9, 2024
Our study shows that anti-IL-17A and anti-TNF? therapy rebalances the immune cell repertoire of lesional skin in psoriatic patients but fails to restore the disturbed immune cell repertoire in non-lesional skin.
- | Humira (adalimumab) / AbbVie
Journal: Adalimumab as a cause of kidney injury in patients with Crohn's disease. (Pubmed Central) - Mar 8, 2024
Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.
- Humira (adalimumab) / AbbVie
NELL-1 Membranous Nephropathy during treatment of Rheumatoid Arthritis with Adalimumab (SUN-082; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_901;
Our patient had a long history of RA but never developed kidney complications associated with her chronic inflammatory autoimmune disease however, the patient developed hypoalbuminemia and NS four months after the initiation of Adalimumab. This is not the first time Adalimumab has been linked with MN.
- Humira (adalimumab) / AbbVie
Estimation of Budget Impact With the Substitution of Biologic Reference Product for Biosimilars in Patients With Rheumatoid Arthritis From the Perspective of Medium Size Healthcare Insurance in Brazil () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2233;
Economic studies play a crucial role in raising awareness within the medical community amid a progressively resource-scarce landscape. The imperative for resource optimization is evident in RA management, where studies affirm no efficacy differences between agents, enabling prescribers to choose agents with an optimal cost-effectiveness ratio.